### Expression and localization of rhoptry neck protein 5 in merozoites and sporozoites of *Plasmodium yoelii*

Joe Kimanthi Mutungi<sup>a,b</sup>, Kazuhide Yahata<sup>a,\*</sup>, Miako Sakaguchi<sup>c</sup> and Osamu Kaneko<sup>a,\*</sup>

<sup>a</sup> Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

<sup>b</sup> Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

<sup>c</sup> Central Laboratory, Institute of Tropical Medicine. (NEKKEN), Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

\* Corresponding authors: Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. Tel.: +81 95 819 7838; fax: +81 95 819 7805.

E-mail addresses: joemutungi@gmail.com (J.K. Mutungi), kyahata@nagasaki-u.ac.jp (K. Yahata), miako@nagasaki-u.ac.jp (M. Sakaguchi), okaneko@nagasaki-u.ac.jp (O. Kaneko).

Note: The nucleotide sequence reported in this paper is available in the GenBank<sup>TM</sup>/EMBL/DDBJ databases under the accession number: AB926016.

Keywords: Plasmodium yoelii; Invasion; Moving Junction; Rhoptry.

Host cell invasion by Apicomplexan parasites marks a crucial step in disease establishment and pathogenesis. The moving junction (MJ) is a conserved and essential feature among parasites of this phylum during host cell invasion, thus proteins that associate at this MJ are potential targets of drug and vaccine development. In both Toxoplasma gondii and Plasmodium falciparum, a micronemal protein, Apical Membrane Antigen 1 (AMA1), and Rhoptry Neck proteins (RONs; RON2 and RON4) form an essential complex at the MJ. A new RON member, RON5, was shown to be important to stabilize RON2 during development and to associate with the MJ complex in T. gondii and also to be immunoprecipitated by anti-AMA1 antibody in P. falciparum. However, the detailed molecular nature of RON5 in Plasmodium is not well understood. In this study, Plasmodium yoelii RON5 gene (pyron5) was identified as an ortholog of P. falciparum and Plasmodium berghei ron5. The pyron5 exon-intron structure was validated by comparing genomic DNA sequences and experimentally determining fulllength complementary DNA sequence. PyRON5 was detected in water-insoluble fractions but no reliable transmembrane domain(s) were predicted by transmembrane prediction algorithms. PyRON5 formed a complex with PyRON4, PyRON2, and PyAMA1 in late schizont protein extract. Taken together, we infer that these results suggest that PyRON5 associates with membrane indirectly via other MJ components. Indirect immunofluorescence assay and immunoelectron microscopy localized PvRON5 at the rhoptry neck of the late schizont merozoites and at the rhoptry of sporozoites. The two-stage expression of PyRON5 suggests that PyRON5 plays roles in invasion of not only erythrocytes, but also of mosquito salivary glands and/or mammalian hepatocytes.

## **Graphic Abstract**



## Highlights

- PyRON5 forms a complex with RON2, RON4, and AMA1 in schizont extract.
- PyRON5, a putative soluble protein, exists in the water-insoluble fractions.
- These suggest that PyRON5 associates with membrane via other complex component(s).
- PyRON5 is expressed in the rhoptry in both merozoite and sporozoite parasites.
- Targeting PyRON5 may prevent cell invasion by both merozoite and sporozoite.

## 1. Introduction

The invasive stages of the phylum Apicomplexa, to which malaria parasites (*Plasmodium* spp.) and Toxoplasma gondii belong, possess a conserved apical complex containing specialized secretory organelles; micronemes, rhoptries, and dense granules, whose contents are sequentially discharged during host cell invasion [1]. The conservation of a microneme protein, Apical Membrane Antigen 1 (AMA1), and Rhoptry Neck proteins (RONs) including RON2, -4, and -5, in both Plasmodium and T. gondii suggests a conserved host-cell invasion mechanism [2 - 6]. In both parasites, AMA1 and the RONs form a complex which is involved in the establishment of a tight adhesive ring-like structure at the parasite-host cell interface, called the "moving junction (MJ)", which progresses from the anterior to the posterior of the parasite during invasion, leading to internalization of the parasite into a nascent parasitophorous vacuole (PV), within which the parasite develops to successive stages [7, 8]. The functional role of RON2 during its interaction with AMA1 at the MJ in T. gondii tachyzoites and P. falciparum merozoites and its association with both RON4 and RON5, is now understood [2, 9]. Although the topology of the RONs in the MJ in P. falciparum has not been conclusively elucidated, immunofluorescence assays along with confocal microscopy showed PfRON2, PfRON4, and PfAMA1 colocalizing at the MJ and immunoelectron microscopy (IEM) revealed PfRON4 localizing on the erythrocyte cytoplasmic side during invasion [10]. It is currently unknown what role RON5 plays in cell invasion in malaria parasites. However, the current model suggests that the RON complex is inserted into the host cell with RON2 having a surface exposed Cterminal ectodomain, part of which serves as a receptor for AMA1 on the parasite surface, while the other RONs are thought to be discharged into the host cell cytoplasm [2, 7, 9].

Due to numerous similarities with human malaria parasites, rodent malaria parasites have been used to complement the study of the human malaria parasites infection of liver, blood, and mosquito cells [10 - 13]. Proteomic analysis demonstrated that RON2, RON4, and RON5 are present in P. falciparum sporozoites in both oocysts and mosquito salivary glands [14]. Myc-tagged RON2 and AMA1 were shown to localize at the rhoptries and micronemes, respectively, in the rodent malaria parasite Plasmodum berghei merozoites and sporozoites [15]. These findings, taken together with the essentiality of RON4 in P. berghei sporozoite invasion of hepatocytes [16], suggest a role for RON proteins in both hepatocyte and erythrocyte invasion. This implies that Plasmodium parasites could employ similar invasion strategies in two distinct life cycle stages. Radio-labelled immunoprecipitation data suggested an AMA1-RON4 interaction in *Plasmodium yoelii* merozoites but there is, as yet, no evidence for the presence of any potential PyRON2 and PyRON5 proteins among the components of the complexes [17, 18].

Here, we describe the primary protein structure of *Py*RON5 and its possible membrane association. We also show that *Py*RON5 forms a complex with *Py*RON2, *Py*RON4, and *Py*AMA1 by immunoprecipitation of blood stage schizont protein extracts. Furthermore, we show that *Py*RON5 is localized at the rhoptry neck in schizont stage

merozoites, and in the rhoptries of sporozoites. These results suggest that PyRON5 may play a role in erythrocyte invasion and salivary gland and/or hepatocyte invasion.

### 2. Materials and methods

#### 2.1. Experimental animals and malaria parasites

*P. yoelii* 17XL (*Py*17XL), obtained from Nagasaki University's BioResource bank (http://www.nbrp.jp/) was maintained in 6 to 8 week old female ICR mice (SLC Inc., Shizuoka, Japan). All experiments conducted in this study were approved by the animal care and use committee of Nagasaki University (Permit number 0912080806-4).

In order to isolate oocyst stage sporozoites, *Anopheles stephensi* midguts were dissected at day 9 post feed, gently crushed in sterile phosphate buffered saline (PBS) in an all plastic homogenizer, and sporozoites harvested from the supernatant after a brief low-speed centrifugation to remove mosquito debris. Similarly, salivary gland sporozoites were harvested at day 17–21 post feed by dissection and homogenisation of mosquito salivary glands in PBS.

## 2.2. Extraction of parasite genomic DNA (gDNA) and RNA, and complementary DNA (cDNA) synthesis

Py17XL-infected blood was collected from mice into saline sodium citrate and passed once through CF11 column (Whatman<sup>®</sup> International Ltd, UK) to remove leukocytes. The pass-through was then treated with 0.15% saponin (Wako Pure Chemical Industries, Ltd, Japan) in PBS, centrifuged, then the resultant pellet was washed in PBS. Genomic DNA was extracted using DNAzol BD reagent (Invitrogen, Carlsbad, CA). Total RNA was isolated from the pellet stored at  $-80^{\circ}$ C in TRIzol (Invitrogen). Complementary DNA was synthesized using SuperScript<sup>®</sup> III Reverse Transcriptase Kit (Invitrogen) with random hexamers after DNase I treatment. To ensure no contaminating DNA remained in the cDNA, a negative control (without reverse transcriptase) was included.

## 2.3. Polymerase Chain Reaction (PCR) amplification, sequencing, and analysis

DNA fragments were PCR-amplified from gDNA and cDNA of *Py*17XL parasite using KOD -Plus- Neo DNA polymerase with a panel of primers (Table 1). The PCR products were treated with exonuclease I and shrimp alkaline phosphatase (ExoSAP-IT, USB Corporation, Cleveland, OH), then sequenced with the same primers used for the PCR amplification and other specific primers (Table 1) using either a 3730 DNA analyzer or ABI PRISM<sup>®</sup> 3130xl genetic analyzer (Applied Biosystems, Foster City, CA). Obtained sequences were aligned using MUSCLE webware [19]. SignalP 4.1 [20] was used to search for signal peptide sequence and the presence of transmembrane (TM) domains was evaluated with Phobius [21] and OCTOPUS [22].

#### 2.4. Antisera production

Anti–PyR	ON5,	anti–PyF	RON2	(PY17X	1319500,
previously	PY(	)6813),	and	anti–	PyAMA1

(PY17X 0916500, previously PY01581) polyclonal antisera were produced by immunisation of rabbits and mice with a mixture of three synthetic peptides for each protein. A cysteine residue was added to the N or C terminus of each peptide to allow conjugation with keyhole limpet hemocyanin (KLH) for immunisation (Table S1). Rabbit antibodies that were affinity-purified using NHS-activated Sepharose<sup>TM</sup> 4 Fast Flow gel (GE Healthcare Life Sciences, Sweden) with the peptide NNHRNDSKLEHSNKNTFD-C for anti-PyRON5 (amino positions acid (aa) 36-53) or C-GKKGENYDRMGQADDYGKSKSR for anti-PyAMA1 (aa 505-526) were found to react most strongly by indirect immunofluorescence assay and Western blot against the protein (data not shown), and were used in the relevant experiments. Mouse anti-PyRON2 and mouse anti-PyAMA1 antisera were used without purification. Mouse monoclonal anti-PyRON4 (mAb 48F8) [17] was obtained from David L. Narum (National Institutes of Health, USA). Mouse monoclonal anti-PyRhopH3 (mAb#32) has been described previously [23].

## 2.5. Protein extraction from parasites, SDS–PAGE and Western blotting

Parasite-infected whole blood was obtained as in section 2.2 and the schizont-rich fraction was separated by differential centrifugation through 13.8 g/100 mL Histodenz<sup>TM</sup> (Sigma–Aldrich Co. St. Louis, MO) in PBS, pH 7.4. The schizonts were washed 3 times with sterile PBS supplemented with a protease inhibitor cocktail tablet. cOmplete, EDTA-free (Roche, Switzerland) and 1 mM EDTA (PBS-PI). The pellet was then treated with 0.15% saponin in PBS as described in section 2.2 and then kept at -80°C until protein extraction. Three sequential extraction procedures were used to obtain crude protein extract from the same pellet. First, the water-soluble fraction (FT) was extracted by three times repeated freeze-thaw at -80°C in PBS-PI and the soluble fraction was obtained by centrifugation at 21,500 × g for 10 min. The waterinsoluble pellet was washed five times with PBS-PI to avoid carry-over of any soluble extract. To verify the completion of this washing step, the freeze-thaw process was repeated once more and extract was saved for the later analysis. Proteins were further extracted in PBS-PI containing 1% Triton X-100 (Tx; Calbiochem, San Diego, CA) for 30 min on ice. The Tx-insoluble pellet was washed five times with PBS-PI-Tx and pellet was once more treated with PBS-PI-Tx and extract was saved for later analysis. Protein was further extracted with PBS-PI containing 2% sodium dodecyl sulfate (SDS; Nacalai Tesque, Japan) for 30 min at room temperature (RT). In all extraction steps, the final parasite concentration was adjusted to  $2 \times 10^6$  schizonts/µL. Proteins were also sequentially extracted from oocyst-derived sporozoites in similar process as for the blood stage parasites except that in this case the pellet was washed three times after each extraction step. The FT fraction from schizont extracts was also obtained by centrifugation at  $132,335 \times g$  for 60 min. The protein fractions were resolved by electrophoresis on 5-20% SDS polyacrylamide gradient mini gels (ATTO, Japan) under reducing conditions (1  $\times$  10<sup>7</sup> schizonts or 9  $\times$  $10^3$  sporozoites for each lane). The protein bands were transferred from gels to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA). The blotted

membrane was immunostained with affinity-purified rabbit anti-PyRON5, rabbit anti-PyAMA1 antibodies, or mouse anti-PyRON2 serum for 1 h at RT followed by secondary incubation with horseradish peroxidase (HRP)conjugated goat anti-rabbit or anti-mouse IgG (Promega, Madison, WI). Normal rabbit IgG (Millipore) or normal mouse serum were used as negative controls. In all cases, affinity-purified primary antibodies and normal IgG controls were used at a final concentration of 2 µg/mL while crude antisera and normal preimmune serum controls were diluted to 1:500. Bands were visualized with Immobilon<sup>™</sup> Western Chemiluminescent HRP substrate (Millipore) and detected using a chemiluminescence detection system (LAS-4000EPUVmini; Fujifilm, Japan). The relative molecular sizes of the protein bands were calculated based on reference to the molecular size standards (Precision Plus Protein<sup>TM</sup> Dual Color Standards; Bio-Rad).

## 2.6. Complex formation evaluation by immunoprecipitation

Immunoprecipitation was carried out as previously described [24]. Proteins were extracted from late schizont parasite pellet once with Tx treatment. The supernatants (50 µL, final 0.5% Tx, corresponding to  $1 \times 10^7$ parasitized erythrocytes) were pre-incubated with 20 µL of 50% protein G-conjugated beads (GammaBind Plus Sepharose; GE Healthcare) in NETT buffer (0.15 M NaCl, 1 mM EDTA, 50 mM Tris-HCl, and 0.5% Tx) supplemented with 0.5% BSA (fraction V; Sigma) at 4°C for 1 h. The recovered supernatants were incubated with 2 µL of rabbit anti-PyRON5, crude mouse anti-PyRON2, rabbit anti-PyAMA1, or mouse anti-PyRON4 antibodies. Normal mouse IgG (Millipore) or rabbit preimmune serum was used as negative control. The suspensions were gently rotated at 4°C for 2 h, and then 20 µL of 50% protein Gconjugated beads was added. After 1 h incubation at 4°C, the suspensions were centrifuged and supernatants were kept at -80°C for further analysis. The beads were washed sequentially with NETT-0.5% BSA, NETT, high-salt NETT (0.5 M NaCl), NETT, and then low-salt NETT (0.05 M NaCl and 0.17% Tx). Finally, proteins were extracted from the beads by boiling at 100°C for 3 min in 1x SDS-PAGE sample loading buffer (2% SDS, 5% 2mercaptoethanol, 10% glycerol, 0.002% bromophenol blue, 62.5 mM Tris-HCl, pH 6.8). Supernatants containing immunoprecipitated proteins were collected after centrifugation and resolved on SDS-PAGE. Proteins were transferred to PVDF membranes, and then probed with the antibodies described in this section.

#### 2.7. Indirect Immunofluorescence assay (IFA)

Schizont-rich whole blood was obtained from Py17XLinfected mouse tail and bled into saline sodium citrate, washed three times with PBS and adjusted to 10% hematocrit. Thin smears were prepared on microscope glass slides and quickly air-dried at RT. Sporozoite samples were obtained in PBS as described in section 2.1, seeded on twelve-well multi-test slides and quickly airdried at RT. The prepared slides were then stored at  $-80^{\circ}C$ with desiccants until use. The smears were thawed, fixed in 4% paraformaldehyde containing 0.0075% glutaraldehyde [25] (Nacalai Tesque) in PBS at RT for 15 min, rinsed with 50 mM glycine (Wako) in PBS. Sporozoites were permeabilized with 0.05% Triton X-100 in PBS for 5 min. Samples were then blocked with PBS containing 10% normal goat serum (Invitrogen) at 37°C for 30 min. Next, samples were singly or doublyimmunostained with primary antibodies using purified rabbit anti-PyRON5 (final 2 µg/mL), mouse monoclonal anti-PyRON4 (rhoptry neck marker, final 2 µg/mL), crude mouse anti-PvRON2 serum (rhoptry neck marker, final 1:500), mouse monoclonal anti-PyRhopH3 (rhoptry body marker, final 2 µg/mL), or crude mouse anti-PyAMA1 (micromene marker, final 1:500) at 37°C for 1 h. Normal mouse or rabbit IgG (Millipore) or normal mouse serum was used as negative control. This was followed by 3 washes with PBS then incubation with Alexa Fluor<sup>®</sup> 488 goat anti-mouse and/or Alexa Fluor® 594 goat anti-rabbit antibodies (Invitrogen; final 500 times dilution) in blocking solution at 37°C for 30 min. Parasite nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI; Invitrogen, final 0.2 µg/mL). The stained samples were mounted with ProLong<sup>®</sup> Gold antifade reagent (Invitrogen) and cover slips onto microscope slides. Differential interference contrast (DIC) and fluorescence images were obtained using a fluorescence microscope (ECLIPSE 80i; Nikon, Japan) with a Plan Fluor 100x/1.30 oil immersion lens and a charge-coupled device camera (VB-7010; KEYENCE, Japan). Images were processed using Adobe Photoshop CS (Adobe Systems Inc., San José, CA).

#### 2.8. Immunoelectron microscopy (IEM)

Schizont and sporozoite samples were fixed in a mixture of 4% paraformaldehyde containing 0.1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, at 4°C for 15 min. Fixed specimens were washed with 0.1 M phosphate buffer, dehydrated with ethanol series (30%, 50%, 70%, then 95%), each time at 4°C for 5 min, and embedded in LR White resin (London Resin Company, UK) as previously described [26]. Thin sections prepared by ultramicrotome (Reichert-Jung, Austria) were blocked in PBS containing 5% non-fat milk (Becton, Dickinson and Company, USA) and 0.0001% Tween 20 (PBS-MT; Wako) at 37°C for 30 min. Grids were then incubated with crude rabbit anti-PyRON5 serum in PBS-MT at 4°C overnight. After washing with PBS containing 5% Blocking One buffer (Nacalai Tesque) and 0.0001% Tween 20 (PBS-BT), the grids were incubated at 37°C for 1 h with goat anti-rabbit IgG conjugated to 15 nm gold particles (EY Laboratories, San Mateo, CA) in PBS-MT, rinsed with PBS-BT, and fixed at RT in 0.5% OsO4 (Nacalai Tesque) for 5 min to stabilize the gold. The grids were next rinsed with distilled water, dried, and stained with uranyl acetate and lead citrate. Samples were examined at 80 kV under a transmission electron microscope (JEM-1230; JEOL Ltd., Tokyo, Japan). Final processing of the images was performed using Adobe Photoshop CS.

## 3. Results

## 3.1. Determination of pyron5 gene and PyRON5 protein primary structure

At the time of this study, the PY02282 gene (currently PY17X 0713300) had been identified as an ortholog of

PfRON5 (PF3D7 0817700, previously MAL8P1.73) in the Plasmodium database PlasmoDB [27]. We thus designated PY02282 as pyron5. The sequence of this gene was not completed. Nucleotide alignment using ClustalW between *pyron5* and *pfron5* open reading frames (ORFs) found the 3' side of the pyron5 missing. A BLASTN search was performed against P. berghei, using an orthologous *pyron5* sequence as a query, and the complete gDNA sequence of pbron5 (PBANKA 071310) was identified. To complete and verify the exon-intron structure, DNA fragments covering the entire ORF were PCR-amplified from *Py*17XL cDNA. Fragments representing the 5' part and the middle part were amplified with PyRON5.F2-5U and PyRON5.R3, and PyRON5.F0 and PyRON5.R2 (Table 1). The pyron5 3' end was amplified using a forward primer based on the PY02282 3' end (PyRON5.F9) and reverse primers based on pbron5 3' end; PbRON5.R4 (based on the pbron5 3' ORF end) and PbRON5.R2 (based on the pbron5 3' UTR).

The full length ORF of *pyron5* was found to be 3,447 bp, distributed among 31 exons and encoding a protein (*Py*RON5) of 1,148 amino acid residues. The *pyron5* cDNA sequence obtained from *Py*17XL completely matched the *in silico* prediction of the *pyron5* cDNA sequence of the *Py*17X isolate described in PlasmoDB.

Multiple alignments of RON5 amino acid sequences were obtained using PyRON5, PfRON5 (ADV19050), TgRON5 (ACY08774), and the RON5 homolog of Theileria equi (BEWA 043030, designated as TeRON5 in this manuscript) [28], which was identified by TBLASTN search against EuPathDB transcripts database using PyRON5 amino acid sequence as a query (Fig. S1) [29]. TgRON5 was proposed to be cleaved into 3 products; pro, RON5N, and RON5C domains at a sequence motif of "SFVE" or "SFVQ" by subtilisin-like protease, TgSUB2 [2, 30, 31]. However this motif does not exist in the other 3 RON5 sequences. SignalP 4.1 predicted a putative endoplasmic reticulum (ER) transport signal peptide at aa 1-20 at the PyRON5 N-terminus (Fig. 1) similar to TgRON5, PfRON5 [5, 32] and TeRON5, suggesting that RON5 proteins are targeted to the secretory pathway. TM domains were not predicted by Phobius and OCTOPUS for PyRON5. Amino acid alignment revealed that PyRON5, PfRON5, TgRON5, and TeRON5 had 5 conserved cysteine residues, 3 (at aa 341, 702, and 773) in the region corresponding to TgRON5N and 2 (at aa 804 and 858) in the region corresponding to TgRON5C, which might play important roles for the protein conformation and function (Fig. 1 and Fig. S1). Other 4 cysteine residues of PyRON5 (at aa 262, 345, 713, and 733) were found to be conserved with PfRON5 (Fig. 1 and Fig. S1). There was a hydrophobic region at aa 553-577 in PyRON5 that was conserved among 4 RON5 amino acid sequences and not predicted to be a TM domain (Fig. 1, S1, and S4).

#### 3.2. PyRON5 was detected in the water-insoluble fractions

Anti-*Py*RON5 detected multiple bands of various sizes from FT, Tx, and SDS fractions (Fig. 2A). Among 5 strongly reacted bands of these (~131-, ~87-, ~33-, ~31-, and ~26 kDa; Fig. 2A arrowheads) seen in the FT fraction, the largest ~131-kDa band was about the same size as the calculated full length protein after excluding the putative signal peptide (129 kDa) based on its amino acid sequence. The band around 131 kDa in the water-soluble fraction was detected even after centrifugation at > 130,000 × g for 60 min (Fig. 2B arrowhead). Because these bands were reproducibly observed, we consider that the ~87-, ~33-, ~31-, and ~26 kDa bands are physiologically processed products. The ~131-kDa band was also detected in the Tx and SDS fractions. The ~87-kDa band was more prominent in the Tx fraction than in the FT fraction, and much reduced in the SDS fraction. The bands at ~33-, ~31-, and ~26 kDa were dramatically reduced in intensity in the Tx and SDS fractions, suggesting that these products do not associate with the membrane. No bands were detected with normal rabbit IgG.

## 3.3. Complex formation of PyRON5 with PyRON4, PyRON2, and PyAMA1

The reactivity of mouse anti-PyRON2 and rabbit anti-PyAMA1 were confirmed with Py17XL late schizont extract by Western blotting (Fig. S2). Immunostaining was performed for proteins immunoprecipitated with antibodies against these proteins (Fig. 3). PyRON4 (~140kDa), PyRON2 (187-kDa processed form), and PyAMA1 (60 kDa) were detected in the fraction immunoprecipitated with anti-PyRON5. In the reciprocal experiments, PyRON5, a high intensity ~131-kDa band, was detected in the fractions immunoprecipitated with anti-PyRON4, anti-PyRON2, and, less intensely, with anti-PyAMA1. PyRON5 ~87-kDa band (arrowhead in Fig. 3) was not detected even in the precipitate with anti-PyRON5, suggesting that the epitope region in the ~87-kDa PyRON5 product is not recognized by immunoprecipitation with this anti-PyRON5 antibody. In the precipitates with anti-PyRON2, anti-PyRON4, and anti-PyAMA1, all of these proteins were detected, except PyRON2 in the precipitate with anti-PyAMA1, which is consistent with previous reports that failed or had difficulty to detect PfRON2 in precipitate with anti-PfAMA1 [3, 4]. The band detected at ~100 kDa by anti-PyRON5 antibody was seen only in precipitates with rabbit control and anti-PyRON5, not in the Tx extract input, indicating that this is unrelated to RON5. Mouse and Rabbit control antibodies did not immunoprecipitate PyRON2 or PyAMA1, but a faint PyRON4 band was detected, which served as a background signal for RON4. This specific coimmunoprecipitation indicates complex formation among PyRON5, PyRON4, PyRON2, and PyAMA1.

#### 3.4. PyRON5 located at the rhoptry neck of the merozoite

The localization of PvRON5 at the merozoite stage was evaluated by co-staining PyRON5 with the known rhoptry neck markers, PyRON4 and PyRON2, the microneme marker, PyAMA1, and the rhoptry body marker, PyRhopH3. In a segmented schizont, PyRON5 antibody produced a punctate pattern of fluorescence and each signal was located at one end of each merozoite. PyRON5 signals overlapped with PyRON4 (Fig. 4A, top panels) but only partly overlapped with PyRON2, whose signal was detected in a wider area than PyRON5 (Fig. 4B, top panels). PyRON5 signals also partly overlapped with PyAMA1 (Fig. 4C) or PyRhopH3 (Fig. 4D) signals. Negative controls did not produce any signal, indicating specific labeling of each antibody and no crosstalk between fluorescence channels (Fig. 4A and 4B, middle and bottom panels). To identify the precise location of *Py*RON5, we performed IEM. Because purified anti-*Py*RON5 did not react with specimen for IEM, we used crude rabbit anti-*Py*RON5 serum. IEM precisely localized *Py*RON5 at the neck portion of the rhoptries in the segmented schizont (Fig. 5), but preimmune rabbit serum did not react (Fig. S3B). Positive IFA image with this crude anti-*Py*RON5 serum and negative image with preimmune serum is provided in figure S3A. Thus *Py*RON5 was identified as a rhoptry neck protein.

## 3.5. *PyRON5 is expressed and localized in the rhoptry of sporozoite derived from both oocysts and salivary glands*

Because *P. berghei* AMA1 and RON2 were previously shown to be expressed not only in merozoites but also sporozoites [15], we evaluated the expression of PyRON5 in sporozoites. Western blot analysis detected 3 bands at ~99, ~64, and ~28 kDa in the extract of oocyst-derived sporozoites (Fig. 6). The ~99-kDa band was found in the Tx fraction only and not detected in the schizont extract. The ~64-kDa band was detected in all FT, TX and SDS fractions and was similar to the broad faint band(s) around ~64 kDa in the schizont extract (arrow in Fig. 2A), which was detected in FT and Tx fractions, but not in the SDS fraction. The ~28-kDa band was strongly detected in water-soluble FT fraction, but only weakly in waterinsoluble fractions, which was similar to the weak ~28kDa band detected in schizont extract in size and the extraction pattern. The bands at ~131 kDa and ~87 kDa detected in the schizont extract were not detected in the sporozoite extract.

IFA revealed that PyRON5 was expressed in both types of sporozoites, one derived from oocyst and the other derived from salivary glands. Signals colocalized with PyRON4 at the apical end of the sporozoites, extending from the mid portion anterior to the nucleus to the apical tip of the sporozoite (Fig. 7). The signals were usually continuous, but occasionally, additional dot-like signals were observed towards the nucleus (Fig. 7 white arrowhead). IEM also revealed precise localization of PyRON5 at the rhoptries in oocyst stage sporozoites (Fig. 8).

#### 4. Discussion

In this study, we experimentally determined the ORF of RON5 in the rodent malaria parasite *P. yoelii* 17XL. Using *P. yoelii*, we showed that RON5 associates with the known MJ complex component proteins, RON2, RON4, and AMA1 in malaria parasites as it does in *T. gondii* [2]. Although TM prediction algorithms did not predict clear transmembrane region in *Py*RON5, a portion of RON5 was not extracted by repeated freeze-thaw procedure, suggesting that RON5 probably associates with membrane. We think that RON5 probably associates indirectly with membranes through interaction with a membrane-anchored protein in MJ complex proteins. RON5 is not only expressed in the merozoite, but also in the sporozoite.

The antibody that recognizes the N-terminal aa 36-53 of *Py*RON5 labeled mature rhoptries both by IFA and IEM and detected ~131-kDa *Py*RON5 product in the precipitates with anti-*Py*RON2, anti-*Py*RON4, or anti-*Py*AMA1 antibodies in schizont extracts, suggesting that the full length of RON5 is able to associate with MJ components. This is different from *T. gondii*, in which the

antibody recognizing the pro-domain of TgRON only detected the pro-rhoptry compartment and did not detect mature rhoptries, and thus did not detect protein in the complex [33]. The homology of the N-terminal side of RON5 among different parasites is not high and reliable alignments could not be obtained. Also both PfRON5 and PyRON5 do not have the cleavage sites ("SFVE" or "SFVQ") present in TgRON5 [33]. Thus, it is impossible to predict the "pro-domain" in PyRON5, if it exists at all, by comparison with TgRON5. Nonetheless, the complex formation of the ~131-kDa PyRON5 product with other MJ complex components suggests that cleavage to form the 26-33 kDa products may not be a prerequisite for complex formation. Alternatively, association of the ~131kDa PyRON5 may be an artifact during the extraction procedure and only processed products that do not contain the N-terminal 26-kDa and ~ 33-kDa region may associate with other components at MJ during cell invasion. For example, the interaction between AMA1 and RONs detected in the schizont extracts is likely artificially achieved as AMA1 and RONs localized in the different compartments at schizont stage. Such artificial interaction may occur in T. gondii extract, for example, when T. gondii extract was immunoprecipitated with anti-TgRON4, a faint  $\sim$ 175-kDa band that appears to be a full-length TgRON5 was also co-precipitated in addition to a ~100kDa TgRON5N band [2]. To clarify this point, future experiments are required using antibodies that react with the central and C-terminal parts of PvRON5.

Our anti-PyRON5 antibody detected a band around ~87-kDa in the *P. yoelii* schizont extract. Based on the molecular weight of 87 kDa, the 87-kDa PyRON5 product is expected to contain an interspecies-conserved hydrophobic region at aa 553-577 in *Py*RON5 described above (Fig. S4). The reduction in intensity of the ~87-kDa band along with the presence of the 131-kDa band in the Tx-insoluble SDS fraction suggests that the C-terminal is involved in *Py*RON5 association with detergent-resistant membrane or the removal of the ~87-kDa product with detergent-resistant membrane.

The amino acid sequence alignment of PyRON5 and TgRON5 suggests that the cleavage event that yields ~87kDa PyRON5 product in P. yoelii schizont appears to be similar to that between RON5N and RON5C of TgRON5 (Fig. S4) [33]. However, the ~87-kDa product was not detected in sporozoites, whereas a ~99-kDa product was detected. Based on the expected cleavage site, the ~87-kDa product probably does not contain two interspeciesconserved cysteine residues at aa 804 and 858, as in TgRON5, but the ~99-kDa product may contain both of these cysteine residues. In T. gondii, the processing of TgRON5N and TgRON5C was dispensable without significant effect on function and rhoptry trafficking [33]. Thus this alternative cleavage may not affect protein function and may be due to differentially expressed RON5 maturases in merozoite and sporozoite.

Robust TM prediction algorithms, Phobius and OCTOPUS, that use statistical models trained with a set of known transmembrane regions did not predict any TM regions in PyRON5. Thus, the existence of PyRON5 in the water-insoluble Tx and SDS fractions suggests that PyRON5 has domain(s) that associate(s) with membrane(s) indirectly. RON2 has undisputed TM domain(s) and thus detection of PyRON5 in Tx and SDS

fractions could be due to its association with PyRON2. Because the ~100-kDa TgRON5N product is the main component in the MJ complex in *T. gondii*, the homologous central region of PyRON5 may be responsible for the MJ complex formation. In this regard, it should be noted that the interspecies-conserved hydrophobic region at aa 553-577 is located in this central region and the Cterminal from this hydrophobic region is relatively conserved among species.

In previous studies, AMA1, RON2, and RON4 were identified in sporozoites in addition to the merozoites [15, 16]. In this study, we show that RON5 is also expressed in both merozoites and sporozoites. Thus all four components forming the MJ complex are conserved between merozoite and sporozoite, suggesting that these proteins play roles in invasion not only of erythrocytes but also of mosquito salivary glands and/or hepatocytes..

## Acknowledgments

We are grateful to T. Yoshimoto, K. Ito, and M. Kaewthamasorn for their valuable comments during experiments, T. Yanagi for support in maintaining rodent malaria parasites, R. Culleton for production of sporozoites, and D. Narum for anti-*Py*RON4 monoclonal antibody. This work was supported in part by Grants-in-Aids for Scientific Research 22390079 and for Scientific Research on Innovative Areas 23117008 (O.K.), and the Global COE Program, Nagasaki University, from the Ministry of Education, Culture, Sports, Science and Technology of Japan. J.K.M. is a recipient of MEXT PhD scholarship, Japan. All experiments conducted in this study were approved by the animal care and use committee, Nagasaki University.

#### References

- [1] Baum J, Gilberger TW, Frischknecht F, Meissner M. Host-cell invasion by malaria parasites: insights from *Plasmodium* and *Toxoplasma*. Trends Parasitol 2008;24:557–63.
- [2] Besteiro S, Michelin A, Poncet J, Dubremetz JF, Lebrun M. Export of a *Toxoplasma gondii* Rhoptry neck Protein complex at the host cell membrane to form the moving junction during invasion. PLoS Pathog 2009;5:e1000309.
- [3] Alexander DL, Arastu-Kapur S, Dubremetz JF, Boothroyd JC. *Plasmodium falciparum* AMA1 binds a rhoptry neck protein homologous to TgRON4, a component of the moving junction in *Toxoplasma gondii*. Eukaryot Cell 2006;5:1169– 73.
- [4] Cao J, Kaneko O, Thongkukiatkul A, Tachibana M, Otsuki H, Gao Q, et al. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in *Plasmodium falciparum* merozoites . Parasitol Int 2009;58:29–35.
- [5] Lebrun M, Michelin A, El Hajj H, Poncet J, Bradley PJ, Vial H, Dubremetz JF. The rhoptry neck protein RON4 re-localises at the moving junction during *Toxoplasma gondii* invasion. Cell Microbiol 2005;7:1823–33.
- [6] Chesne-Seck ML, Pizarro JC, Vulliez-Le, Normand B, Collins CR, Blackman MJ, B.W. Faber, et al. Structural comparison of apical membrane antigen 1 orthologues and paralogues

- [7] Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC. Identification of the moving junction complex of *Toxoplasma gondii*: a collaboration between distinct secretory organelles. PLoS Pathog 2005;1:e17.
- [8] Riglar DT, Richard DW, Wilson, Boyle MJ, Dekiwadia CL. Turnbull F, et al. Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. Cell Host Microbe 2011;9:9–20.
- [9] Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, J. Morlon-Guyot, et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog 2011;7:e1001276.
- [10] Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of *Plasmodium* merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci USA 2011;108:13275–80.
- [11] Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of *Plasmodium berghei* sporozoites injected into skin by mosquitoes. Int J Parasitol 2004;34:991–6.
- [12] Yahata K, Treeck M, Culleton R, Gilberger TW, Kaneko O. Time-lapse imaging of red blood cell invasion by the rodent malaria parasite *Plasmodium yoelii*. PLoS One 2012;7:e50780.
- [13] Frischknecht F, Baldacci P, Martin B, Zimmer C, Thiberge S, Olivo-Marin JC, et al. Imaging movement of malaria parasites during transmission by *Anopheles* mosquitoes. Cell Microbiol 2004;6:687–94.
- [14] Lasonder E, Janse CJ, van Gemert GJ, Mair GR, Vermunt AM, Douradinha BG, et al. Proteomic profiling of *Plasmodium* sporozoite maturation identifies new proteins essential for parasite development and infectivity. PLoS Pathog 2008;4:e1000195.
- [15] Tufet-Bayona M, Janse CJ, Khan SM, Waters AP, Sinden RE, Franke-Fayard B. Localisation and timing of expression of putative *Plasmodium berghei* rhoptry proteins in merozoites and sporozoites. Mol Biochem Parasitol 2009;166:22–31.
- [16] Giovannini D, Späth S, Lacroix C, Perazzi A, Bargieri D, Lagal V, et al. Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa. Cell Host Microbe 2011;10:591–602.
- [17] Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal *Plasmodium yoelii yoelii* YM blood-stage infection. Infect Immun 2000;68:2899–906.
- [18] Narum DL, Nguyen V, Zhang Y, Glen J, Shimp RL, Lambert L, et al. Identification and characterization of the *Plasmodium yoelii PyP140/RON4* protein, an orthologue of *Toxoplasma gondii* RON4, whose cysteine-rich

domain does not protect against lethal parasite challenge infection. Infect Immun 2008;76:4876– 82.

- [19] Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004;32:1792–97.
- [20] Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011;8:785–6.
- [21] Käll L, Krogh A, Sonnhammer ELL. A combined transmembrane topology and signal peptide prediction method. J Mol Biol 2004;338:1027–36.
- [22] Viklund H and Elofsson A. Improving topology prediction by two-track ANN-based preference scores and an extended topological grammar. Bioinformatics 2008;24:1662–8.
- [23] Shirano M, Tsuboi T, Kaneko O, Tachibana M, Adams JH, Torii M. Conserved regions of the *Plasmodium yoelii* rhoptry protein RhopH3 revealed by comparison with the *P. falciparum* homologue. Mol Biochem Parasitol 2001;112:297–9.
- [24] Kaneko O, Fidock DA, Schwartz OM, Miller LH. Disruption of the C-terminal region of EBA-175 in the Dd2/Nm clone of *Plasmodium falciparum* does not affect erythrocyte invasion. Mol Biochem Parasitol 2000;110:135–46.
- [25] Tonkin CJ, van Dooren GG, Spurck TP, Struck NS, Good RT, Handman E, et al. Localization of organellar proteins in *Plasmodium falciparum* using a novel set of transfection vectors and a new immunofluorescence fixation method. Mol Biochem Parasitol 2004;137:13–21.
- [26] Aikawa M, Atkinson CT. Immunoelectron microscopy of parasites. Adv Parasitol 1990; 29:151–214.
- [27] Bahl A, Brunk B, Crabtree J, Fraunholz MJ, Gajria B, Grant GR, et al. PlasmoDB: the *Plasmodium* genome resource. A database integrating experimental and computational data. Nucleic Acids Res 2003;31:212–5.
- [28] Kappmeyer LS, Thiagarajan M, Herndon DR, Ramsay JD, Caler E, Djikeng A, et al. Comparative genomic analysis and phylogenetic position of *Theileria equi*. BMC Genomics 2012;13:603.
- [29] Aurrecoechea C, Heiges M, Wang H, Wang Z, Fischer S, Rhodes P. et al. ApiDB: integrated resources for the apicomplexan bioinformatics resource center. Nucleic Acids Res 2007;35:D427–30.
- [30] Straub KW, Cheng SJ, Sohn CS, Bradley PJ. Novel components of the Apicomplexan moving junction reveal conserved and coccidia-restricted elements. Cell Microbiol 2009;11:590–603.
- [31] Miller SA, Thathy V, Ajioka JW, Blackman MJ, Kim K. TgSUB2 is a *Toxoplasma gondii* rhoptry organelle processing proteinase. Mol Microbiol 2003;49:883–94.
- [32] Curtidor H, Patiño LC, Arévalo-Pinzón G, Patarroyo ME, Patarroyo MA. Identification of the *Plasmodium falciparum* rhoptry neck protein 5 (PfRON5). Gene 2011;474 :22–8.

[33] Beck JR, Chen AL, Kim EW, Bradley PJ. RON5 is critical for organization and function of the *Toxoplasma* moving junction complex. PLoS Pathog 2014;10:e1004025.

#### Figures



Figure 1. Primary protein structure of RON5 in Plasmodium yoelii, Plasmodium falciparum, and Toxoplasma gondii. The solid red lines indicate five conserved cysteine residues among PyRON5, PfRON5 and TgRON5 based on the multiple sequence alignment including Theileria equi RON5 homolog (Fig. S1). The dotted red lines indicate the unique cysteine residues. The solid blue lines indicate the additional four conserved cysteine residues between PyRON5 and PfRON5, making nine-conserved cysteine residues between the two. The short black bold horizontal line under PyRON5 indicates the relative position of a peptide sequence used to generate and purify anti-PyRON5 antiserum. S indicates putative signal peptide. Gray boxes, marked with asterisk, indicate a relatively conserved hydrophobic region among RON5 sequences consisting of multiple conserved amino acids (Fig. S1). The black arrowheads indicate TgRON5 cleavage sites. Pro-domain, RON5N, and RON5C regions in T. gondii RON5 are indicated with cyan, pink, and green colors, respectively.



Figure 2. Western blot of RON5 in *Plasmodium yoelii* blood stage parasites. (A) Equal amount of endogenous proteins sequentially extracted from schizont rich parasite pellet by freeze/thaw (FT), 1% Triton X–100 (Tx), and 2% sodium dodecyl sulphate (SDS) were subjected to Western blot analysis using purified rabbit anti-*Py*RON5 ( $\alpha$ -*Py*RON5) antibody. Pre-Tx or pre-SDS indicates FT or Tx extraction before proceeding to the next extraction step, respectively. Rabbit normal IgG was used as a negative control. Arrowheads indicate the major 5 bands detected in FT fraction around 131, 87, 33, 31, and 26 kDa. Arrows indicate the minor bands around 64 and 28 kDa discussed in the manuscript. (B) The FT fraction from schizont extracts was also obtained by centrifugation at 132,335 × g for 60 min and subjected to Western blot analysis using

purified rabbit anti-*Py*RON5. An arrowhead indicates a band around 131 kDa.



Figure 3. Complex formation of RON5 with RON4, RON2, and AMA1 in *Plasmodium yoelii*. Protein from late schizonts was extracted with Triton X–100 (input) and immunoprecipitation (IP) was performed with purified rabbit anti-*Py*RON5 ( $\alpha$ -*Py*RON5) antibody, mouse anti-*Py*RON4 ( $\alpha$ -*Py*RON4) monoclonal antibody, crude mouse anti-*Py*RON2 ( $\alpha$ -*Py*RON2) serum, purified rabbit anti-*Py*AMA1 antibody, mouse antibodies (mouse control) or rabbit control serum (rabbit control), then detected with a panel of antibodies described above. Arrows indicate the expected bands for each protein. Arrowhead indicates ~87kDa product of *Py*RON5.



Figure 4. Immunofluorescence assay of RON5 with rhoptry neck (RON4 and RON2), microneme (AMA1), and rhoptry body (RhopH3) marker proteins in *Plasmodium yoelii* schizont stage merozoites. Schizontinfected erythrocytes were dual-labeled with purified rabbit anti-*Py*RON5 (red) and (A) mouse anti-*Py*RON4 (green), (B) mouse anti-*Py*RON2 (green), (C) mouse anti-*Py*AMA1 (green), or (D) mouse anti-*Py*RhopH3 (green). Control stainings were done with rabbit preimmune sera or normal mouse IgG to exclude the possible false signals from crosstalk between fluorescence channels. The differential interference contrast (DIC) and merged images with nuclei stained with DAPI (blue) are shown. Scale bar represents 2 µm.



Figure 5. Localization of RON5 in *Plasmodium yoelii* schizont stage merozoites by immunoelectron microscopy. Longitudinally sectioned merozoites in schizont-infected erythrocytes were stained with rabbit anti-*Py*RON5 serum followed by secondary antibody conjugated with gold particles. Schizont stage daughter merozoites exhibiting rhoptries (R) are indicated in the cropped and enlarged images on the right side (i and ii). Arrowheads indicate the apical end of the merozoite. Thick and thin scale bars represent 0.5 and 0.2  $\mu$ m, respectively. Control images stained with rabbit preimmune serum can be seen in Fig. S3B.



Figure 6. Western blot of RON5 in *Plasmodium yoelii* sporozoites. Equal amount of endogenous proteins sequentially extracted from oocyst-derived sporozoites by freeze/thaw (FT), 1% Triton X–100 (Tx), and 2% sodium dodecyl sulphate (SDS) were subjected to Western blot analysis using rabbit anti-*Py*RON5 ( $\alpha$ -*Py*RON5) or preimmune sera. Arrowheads indicate 3 detected bands around 99, 67, and 28 kDa.



**Figure 7. Immunofluorescence assay of RON5 with rhoptry neck marker protein, RON4, in** *Plasmodium yoelii* **sporozoites.** Sporozoites obtained from ruptured mature oocyst (top panel) or from salivary glands of the mosquitoes (bottom 4 panels) were stained with purified rabbit anti-*Py*RON5 antibody and mouse monoclonal anti-*Py*RON4 antibody. Rabbit normal IgG and mouse normal IgG were used as negative controls. The differential interference contrast (DIC) and merged images with nuclei stained with DAPI (blue) are shown. Dot-like signals are indicated with white arrowhead and parenthesis. Scale bar represents 2 μm.



Figure 8. Localization of RON5 in *Plasmodium yoelii* sporozoites by immunoelectron microscopy. Sectioned mature oocyst stage sporozoites were labeled with rabbit anti-*Py*RON5 serum. Cropped and enlarged image is shown below. Scale bars represent 1  $\mu$ m. Rhoptry (R) is indicated. Control image stained with rabbit preimmune serum can be seen in Fig. S3C.

### Table 1.

Primers used for PCR amplification and sequencing of pyron5.

Primers for PCR	
PvRON5.F2-5U	GAAAGCCATTTGCATTTATTTGTGTGTG
PyRON5.R3	CATTTCGGTGATTGTTCTTAAATAGTGAA
PyRON5.F0	ATGAAATTGAGTATACTATTTTATGTGG
PyRON5.R2	GCATAGTATTCTTTAATATTGCTT
PyRON5.F9	CATGGATACTTCTTGATAAATTGTCC
PbRON5.R4	TTAAGGTATTCTTGTATGAACAATAATTTC
PbRON5.R2	CAACCACATACATATATATATGTTTGC
Primers for sequencing	
PyRON5.F1	GTGGGGTTTATAGATATGTGTT
PyRON5.F2	GTAAACCAGCTATTGTTCCTAT
PyRON5.seqF0	GCAACTATGTATTCTATAGATTC
PyRON5.seqF1	GGTTATGGGATGAGATTCAGA
PyRON5.seqF2	GACAGTGTTGTTACTGTAAAAG
PyRON5.R0	CTCTTCTTTGATTAGTATCTTGAG
PyRON5.R1	CATCATAATATTTACATCTTGTAG
PyRON5.seqR0	CAATGGTGTTTTGTATATGTTTAG
PyRON5.seqR1	CCATCTAAAAAGAAATCCAACAT
PyRON5.seqR2	CTTGATTTGGATAATCCGATGT

### **Supporting Online Material**

## Expression and localisation of rhoptry neck protein 5 in merozoites and sporozoites of *Plasmodium yoelii*

Joe Kimanthi Mutungi<sup>a,b</sup>, Kazuhide Yahata<sup>a,\*</sup>, Miako Sakaguchi<sup>c</sup> and Osamu Kaneko<sup>a,\*</sup>

<sup>a</sup> Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

<sup>b</sup> Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

<sup>c</sup> Central Laboratory, Institute of Tropical Medicine. (NEKKEN), Nagasaki University, Sakamoto, Nagasaki 852-8523, Japan.

\* Corresponding authors: Tel.: +81 95 819 7838; fax: +81 95 819 7805; E-mail address: kyahata@nagasaki-u.ac.jp or okaneko@nagasaki-u.ac.jp

## Supplementary Table and Figures

Figure S1. Multiple sequence alignment of RON5 amino acid sequences. Amino acid sequences of *Plasmodium yoelii* RON5 (*Py*RON5, in this study), *Plasmodium falciparum* RON5 (*Pf*RON5, ADV19051), *Toxoplasma gondii* RON5 (*Tg*RON5, ACY08774) and *Theileria equi* RON5 homolog (BEWA\_043030) were used to make a multiple sequence alignment using MUSCLE webware. Periods and colons indicate semi-conserved, and asterisks indicate conserved amino acid residues. *Tg*RON5 pro, *Tg*RON5N, and *Tg*RON5C regions are indicated above the alignment with cyan, pink, and green, respectively. Cleavage sites of *Tg*RON5 proposed or confirmed by Beck et al (2014) [1] are indicated with pink box. Signal peptide sequence predicted by SignalP4.1 (with sensitive D-cutoff values) are boxed with dark green and white letter. Cysteine residues conserved among at least 3 spp. are highlighted with white letter and red box and cysteine residues not conserved with white letter and black box. A hydrophobic region consisting of conserved amino acids among 4 spp. is masked with gray box.

Figure S2. Western blot of mouse anti-*Py*RON2 serum and rabbit anti-*Py*AMA1 antibody used in the study. Schizont extracts with 1% Triton X-100 was subjected to Western blot with crude mouse anti-*Py*RON2 serum, normal mouse serum, and purified rabbit anti-*Py*AMA1 antibody. Mouse anti-*Py*RON2 serum reacted with >250-kDa consistent with the full length of *Py*RON2 (expected MW = 252 kDa after excluding signal peptide) and three other bands at ~215, ~183 kDa, which were detected most strongly, and 82 kDa. No band was detected with control normal serum. Purified rabbit anti-*Py*AMA1 reacted with a single 60-kDa band as expected [2]

Figure S3. Indirect immunofluorescence assay with rabbit anti-*Py*RON5 crude serum and its preimmune serum and immunoelectron microscopy images with rabbit preimmune serum for anti-*Py*RON5. (A) Schizont-infected erythrocytes were labeled with crude rabbit anti-*Py*RON5 (red) or its preimmune serum. The differential interference contrast (DIC) and merged images with

nuclei stained with DAPI (blue) are shown. Scale bar represents 2  $\mu$ m. (B) *Plasmodium yoelii* schizont stage merozoites and (C) sporozoites in oocyst are shown. Scale bars represent 0.2 and 1  $\mu$ m for merozoite and sporozoite images, respectively. Arrows indicate rhoptry (R). No gold particle signals were detected.

Figure S4. Primary protein structure of RON5 in *Plasmodium yoelii*, *Plasmodium falciparum*, and *Toxoplasma gondii* and schematics of the expected processing of *Py*RON5. Top panel was explained in the legend of figure 1. In the bottom panel, the solid red lines, the solid blue lines, and the dotted red lines indicate conserved cysteine residues among *Py*RON5, *Pf*RON5 and *Tg*RON5, conserved cysteine residues between *Py*RON5 and *Pf*RON5, and unique cysteine residues in *Py*RON5, respectively. Gray boxes indicate a relatively conserved hydrophobic region among RON5 sequences consisting of multiple conserved amino acids. C-terminal from this hydrophobic region is more homologous than the N-terminal from this region (Fig. S1). N-terminal region having no homology with *Tg*RON5, a region having some homology with *Tg*RON5N, and that having clear homology with *Tg*RON5C are shown with yellow, pink, and green, respectively. Potential cleavage sites are indicated with waving lines.

### References

- [1] Beck JR, Chen AL, Kim EW, Bradley PJ. RON5 is critical for organization and function of the *Toxoplasma* moving junction complex. PLoS Pathog 2014;10:e1004025.
- [2] Narum DL, Ogun SA, Thomas AW, Holder AA. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal *Plasmodium yoelii yoelii* YM blood-stage infection. Infect Immun 2000;68:2899–906.

protein	amino acid positions	sequence
PyRON5	36-53*	NNHRNDSKLEHSNKNTFD-C
PyRON5	448 - 461	APFKFFRDPQDKSY–C
PyRON5	1110 - 1138	C–IVNLKNATFTLNGILNFVIKAEKGNDN
PyRON2	1199 – 1213	C–NQNEYQRQNQIKNQN
PyRON2	1929 – 1942	C–GKWQKERQQGRLKE
PyRON2	2110 - 2122	C-NEIHNNTRGNYHY
PyAMA1	289 - 303	C–ESASDQPKQYERHLE
PyAMA1	336 - 352	C–KSHGKGYNWGNYDSKNN
PyAMA1	505 - 526*	C–GKKGENYDRMGQADDYGKSKSR

Table S1. Amino acid sequences of the peptides used for immunization

Cysteine residue was added to the N- or C-terminus of each peptide to conjugate with KLH. Asterisks indicate peptides that gave the best antibody after affinity purification.

## Fig. S1. Multiple sequence alignment of RON5 amino acid sequences

TgRON5 BEWA_043030 PyRON5 PfRON5	signal peptide MAEFTWRPLLMSLPKMIAFFHILLFSG MIGSGSKSRIFYYLIILFLVI MKLSILFYVVASWYAS MLKYTLLIYIIAGYFIS 	<b>TgRON5 pro-c</b> GALA <mark>AAAGSPAADLVASVQTVSNER</mark> INLKNVYRVYALSGEFDANGNGITQ SEIG SEIS	Iomain KDLYARDTQPTARTGIDIGVS NSLTSTTIPTTINQEQSTDEN GKLHDVFVPKNIS NKLFDTLLPRNV	SFTQQASGNARTFEIRQHGSG NKSESIDSVNKVPDLKSSDQL L	iPPRPAPRRAAAVAD .FPKPDSQKNEVDQS .FKNNHRNDSKLEHSNKN .FKKPKPFKKNEIKK	DIFGS GHKPIDQLPPS TF GI
TgRON5 BEWA_043030 PyRON5 PfRON5	EDFSPPPMNVAGAPLRDMGVHFLE DDYDEDDVRGIDEKSGEISRYTLGVDC DNFEKKLLNDSN DKDEKSIMKNVD	ATDGK I E <mark>@</mark> TGQGAGARPPFFRGGVD QewlrrenaakvvGSKLP	PTEIHEIVQSRTVGPADYDEE ASTSVGYNKF SINVMFDPF SIDVMFEPF * * ::	ERPEQTPDYLSPTDVVTLQRF RTHTLEPI-LSAQKTL RMKKVVPSKMRKQHIV RVKRFVPSRTRKTHVV * :	VSSANASNSPLLEDPVQ GGVIQSLVDNES GGFTQNSVDQAD GGLSQSISDPGD *	VCLSRRKPTYT ILRRKYSQK VEKGKYETA VEKSKYEKA *
TgRON5 BEWA_043030 PyRON5 PfRON5	CHLLHEFAATSVIVEESGNLVCEDKAF VKIQHDLSLA LRFVENMNKQ VRFFENIKNE	PLTVAEKRKINDAVKAGRTPQATGG ITRETAQVVSLLTSGELQKLRMK MVVLAKEMNYALKNEKHTTLE-G MINMSSKINKQLDSQDISSLN-N :: :	QSSRPPNPTVSPSKAGAAPQN HPLVFQRLVEF YNRLTSIMKES FKRASEVLKES :	Proposed NAASRQAV <mark>SFVE</mark> QENSEASMF PLQTQHALNILLSKDM-NRMK SLATMYSIDSIKNANI-VNFS SLATMHSLDIIRNDGS-VDFS : :::::::::::::	I TgRON5N PTANTEQASATTEDTKIA RYNKNWYSYAKNDDK KYNTDWYAKATMKDK KYTLDWYSKANMREK *	SAATDSGDYGE K Y Y
TgRON5 BEWA_043030 PyRON5 PfRON5	AAAGESAQEGDRPPPYNPD-ADEAGVF ALLDELRNY <mark>G</mark> GNKALYASNIKQPKKMF DAAKHIQNTIDKLFKPS-NKKKSVF SIEKSIQKIMNKLFKKARKKKKNMF	PRAVQEAYEEARPLQ-EATIDKFKQ (KSREDVYKKLELFHNDYQ <mark>G</mark> QLVVR (EKKIDENIKQLETDLLLQRFVM (KKKIDANIEQLEMDLLVQKFIT : : : : : :	DAAAAAEAADHFAQVSAFNAN ENQISEKILRTFEQQSGL-YI DNSNVSMLLKKYEDSGDDKYN ENLNASKLLKLYDDSAND-YV : : : .	MQSALTKISAGYHLRAGAHVV IAPLYNSIS MAPSYTDV <mark>C</mark> VSPMHTDV <mark>C</mark> :	/LSA <mark>C</mark> KRLVEAVAANPPG Ps NQ GQ	PGTVIPLEELR IGNKWLLSKFE LGHPILSYVFE LGSIILSYMFE * :
TgRON5 BEWA_043030 PyRON5 PfRON5	MQLVATLTQDFALAQAFIDYAIHIVHS QYFSQSANLNLDLLGKTA STYKHSVNNKLDSFKKYL KAYKSSINHDISYFQKYL	SAIETLTPQMVANALLELSGIEELI YSLIGRFML PKLTTKLTK PRLKYRIQN : .	NHTARVKSRLAARGQDSPANV MVENGTVLPTSF MVENGHIILVDF MIQKGTLLLLEK : .*	VRKEIVQESFRQLKVELFQEI PSSQVALSSLT RRFEQSLDAFK KGLDDSLYTFK : ::	VTRV <mark>@</mark> ELMDDPESFLET TILSNIMEGI NKVSNLMN SKISDIME :*:	VPIIVGTTPTA VEPTT 

## Fig. S1. Multiple sequence alignment of RON5 amino acid sequences (continued)

TgRON5 BEWA_043030 PyRON5 PfRON5	PLRTGGHLGADYIIHLRNDLCDVTASDAQIFPSAPADEGLQGFPRHNLGERLVGWMDVMARTKTARKEVFKIIDFTKAKDVLLFASETGKARYATLQAPAAPAPSFYGITTSG FLGKKKYYGFMNMCDVKCAEGLFKPKSNFFYKELLNKQLEILKWVTAF-YNDDLLRIDTSAQKLLLEIMYRTTRDPGFLRSYKSVRLNIKSE KKVGFIDMCSKKCFDDTVEINYKLDKYDIKLSPQDTNQRRGDLTRMVLYY-YKEIINHIEANADIVLIMLLHLSSSAKTIESGRLDIDIA KKFGFNDMCTDKCMDETIKADYDLSEYKNEFSPSKTAQRRADLVKLLMYY-YRDKIYNIETSADVVLIMLLYLNSANELSEKGYLDVSSI * ::* :
TgRON5 BEWA_043030 PyRON5 PfRON5	MKSKFFDMYLHQSGFMKLQRHGNDNSRQRFMHRVTLLQNDGILPQLPLEADYELMELNAAMQKNFVAANKSIFSRRAARHSKYGYLDL©DVA©YQKIDRLHNDVMTNVFFSLDTTLMK FEDKDKSFIELDTPIPVPIKFQKLERVTKNTGQLQDVTDENKPTKSPIMGKFKIFMSRFLSGFRKQGSSVDNKALSSSIVPYEVFK-TPKNIVASLDNLFLDTFYNIADYI QTTDKHNLIHLAKIAPFKFFR-DPQDKSYSASIFAIDDIM STDDEFNLINKTKIAPFNFFREETQEKTGNESIFAIDDII :
TgRON5 BEWA_043030 PyRON5 PfRON5	IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARRLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARRLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARRLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARRLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVHRSYGIAKAFFQLGARQQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVAFFQLGARQQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVAFFQLGARQQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVNYENLRHGEFTLDTVRMRDALVRYTNMLKADPITRDLMSLVIHTWIHIRGVRNAAMGFKNSQ   IVAKVAFFQLGARQHIADPNLGMWARLFVHWASHNEVKQMQGQKVVKVKVKVKSLASSKTLGAVFRWLNMNEYTSSDVNFLGKNYSDEIQNLYSASYGFVQSKKIKTQSFITSKIRNVGFLLRWFNYNKTPSKNINFLVNNFS
TgRON5 BEWA_043030 PyRON5 PfRON5	KLNESMNASAIGAVFAKLWYESDISVVAPHQELKPFGAPLASMALQIGFFLHTVVEEYKMSLL GSLKGFFRGLIKFGFKGRFRPKTYAQLYEFLEPHVVNSGKYLNSLDIISSMV GNFSAAIKKIFTLGKSGA-NPKNYDDLINFSETDYLLRTKKADAVQRIINQTI GNFSSALKKIFTLGKSGR-NPRNYNDLVNFSEVDYLLRTSKANNVQRIINQII *:.*:**:**:**:***
TgRON5 BEWA_043030 PyRON5 PfRON5	KMFRERFLYRFYMQGQGSKVDFNTPTLLIHALVASWMDPSLDRLELSSRTIPNAKKLFWYYWVNENGPSNAATRIVLTGCKKYTF-LLPGVVRSVTSSTS-EVVEAGSNILKIDKI   SKFKDLFLSKPAIPSPIIQYITVFVGLWAKGASGDFSMSDINMDRVRKTFFLSYVSNGKSLADMATNIIMDNCKVGNHALHLGCISKISSNNKCKQIYV   KILKKKFFSGEYTPTLFAQYVSLFLSLWVFEGEKDISMNNPNISRFKKIFFLSFLVHNSGVVEKATEIICKSCQKKTKKIVLGCIDDYGGKTKRKILGIFSKKCKPAIV   RMLKKKFLSSSYTPTLLAQYMSIFLSLWVFEGENNISLQNPNISRFKKIFFLTYFVHEKGPVEKAVDIIYNKCRMKTDKIVLGCIHDYGGREKKKLLGLISRKCKPTKI    *: : : *: :<

## Fig. S1. Multiple sequence alignment of RON5 amino acid sequences (continued)

	TgRON5C
TgRON5 BEWA_043030 PyRON5 PfRON5	ILKRSSLEAYMNHLQATYDDPLTIVQVALDLAARCEGYSAAKDQPAQAMRGPARVRRATGESTTFTIRGGGVQGGTMSFVEAEADDERKEDSEDNTVDLSEQDQDSSFVQLKKLFNRRGS   SLKSNKLKKVLKMLEATFHDPLDIIRLASDTARRCLAQ   PIEKKSVRKILKVLMTTLSDPLDILKIAVDLSTRCKYY   SIRKRSIRKILNKLMSSLNDPVDILRIAVDTATRCDHF   SIRKRSIRKILNKLMSSLNDPVDILRIAVDTATRCDHF   SIRKRSIRKILNKLMSSLNDPVDILRIAVDTATRCDHF
TgRON5 BEWA_043030 PyRON5 PfRON5	SAAGQAVQTDAQPLPKAVQTDAQPLPKVRRGGPDVDASAVILGSRFMLDLWCSKYREMLVEKLSGISTKDATVMQQEISKVFSAVSSIKIAIPDYKDL-WDFSLRCDWMDGYPD KKQPRPRQSMKRSKPYKYFPLAKKTIKVPHYMDRLMLHSEFSHRIHCYKAQKRLVKEMIKSLSSAVSEDSARKIISTVFSSYRSIEIKQVGMANSSYRLICPFMYDAPE DDSSSKKKKHKENYDLFVKSELSLRHTCAVVTKKLVQKSIKRVSRLKDFSEAPSIIEQTLDSVQYLKMRNHRDPNSSFTVLCPFMQGTDK NRSKNIDNVKTKKNKINYEIFVKSELSIRYICADVTKNVVKKIIRDVSRLKNMREAQNVIDNGLNSVQYLKIRNYRDKESSFTILCPFMEGNDK : : : : : : : : : : : : : : : : : :
TgRON5 BEWA_043030 PyRON5 PfRON5	AEKMRAARAEMVTYAMAKASTGKRLKRMLQKVRSWIRKKAFAAARKLKSLKNRISTAFGRGKPPKAKVPDWAVVNAGVGMWTGKVFSTDLTFNEDEMSGDG ELR-NIHQLNIIKYVISKAVSKARFSPERKRLLTSLQSQPHKLYPTIQMEPLADLPGGVLVGTRKYNGVSYSGGYAPLEKIAYPDNVVVKPGEGRLVYDGSGFVPELMALRETVNVES HIR-DLERSQIISYVL-KNVGIYNLFKGKLHNLFSKSINIKEGVKSDSVVTVKVGGRKFNGNLFVGGYNLNVNDIDQNTLHIGLSKSRKVYNGTKFVDELDILKEE-GIKD NIR-ELERTQISLFIH-KNIGMSRIIKGKLINIFKKTLNMREGIKSDSAISIKVGARKYNGIIFTGGYQLNVDNLDQNTLHIGLSKTRKVYDGRKYVDELEILKGD-GVKN : : : *: * : * : : * : : *
TgRON5 BEWA_043030 PyRON5 PfRON5	PHEPIRVMSWKQNHFTTFASSSTNAERNYVLVKKGDDSHCWATREALVHKGWSGIPVYQYAEPAGFWLQE-VSPSNQPFVVNWDG-YLTTSDNLTLQDIDINA ISVRFEGGYNKYYYNMTDGTQVDERNFAIDSPDFIVKSHVLTTANALIKLGFDMGRIIWCGYKHGWVADFVLSEVVGDTDVPVFNGRYWLLSRELRVEDLVGPDMKIK- IIVKGIDEDNERLYVLSTGERVSEFDYAKENPNANIIIFDGNNYISSYALREIGLENERIVWAGNTVGWTAEFALGN-ISDRPIPIFDGSAWILLDKLSIKNILGNFLPKNV IYMKGLNEDNERIYELQNNMRVSEFDYAIQNPDANIIVFDGNNYISSYALREIGLENERIVWAGPSVGWTAEFALSA-ISDNPLPIFDGSAWVLLEKLSIRSILGKHLPSDV :. :: : : : : : : : : : : : : : : : : :
TgRON5 BEWA_043030 PyRON5 PfRON5	SSDSLKSHAVMRIVDSNGKTIYQGPPTGVVQTQGGVVTLGSIRNLVSGVHSTGDSVEVRVTASGPQLTSVADLDTQFKEIPDL DGDEIKMENIDKYNIRIVNTNNEVMNLNKDSNKESSQSGDSPSNSAEGSFSTILGNITPGGVKNLVKDASYIPERNTLVIDLDAPDFVYSIGGNL NGNLLAKDINFIILNKDGKAILKN-TMPIVNLKNATFTLNGILNFVIKAEK-GNDNEIIVHTRIPDFVYSIGGNL NGNSLANTVNFVILNKDGKPILKN-TTPVINLKYATFTLSGIVNFVIKAEK-GIGNEIIVHTRIP

Fig. S2. Western blot of mouse anti-*Py*RON2 serum and rabbit anti-*Py*AMA1 antibody used in this study.



Figure S3. Indirect immunofluorescence assay with rabbit anti-*Py*RON5 crude serum and its preimmune serum and immunoelectron microscopy images with rabbit preimmune serum for anti-*Py*RON5.



**(B)** 







# Figure S4. Primary protein structure of RON5 in *Plasmodium yoelii*, *Plasmodium falciparum*, and *Toxoplasma gondii* and schematics of the expected processing of *Py*RON5.



